Commonwealth Equity Services’s Oramed Pharmaceuticals ORMP Stock Holding History

Commonwealth Equity Services’s Portfolio ORMP Stock Details ORMP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-30,014	Closed	-$194K	–	3764
2022 Q3	$194K	Buy	30,014 +500	+2%	+$4.05K	﹤0.01%	3192
2022 Q2	$135K	Buy	29,514 +1,950	+7%	+$10.4K	﹤0.01%	3310
2022 Q1	$238K	Buy	27,564 +464	+2%	+$4.75K	﹤0.01%	3166
2021 Q4	$386K	Hold	27,100	–	–	﹤0.01%	2746
2021 Q3	$595K	Buy	27,100 +400	+1%	+$6.81K	﹤0.01%	2341
2021 Q2	$357K	Hold	26,700	–	–	﹤0.01%	2751
2021 Q1	$271K	Buy	+26,700	New	+$219K	﹤0.01%	2865

Other funds holding ORMP

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Lindbrook Capital Calabasas, California $1.08B AUM 10.14% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Group One Trading Chicago, Illinois $52.2B AUM 104.56% 1-Year Est. Return

Citigroup New York $235B AUM 32.99% 1-Year Est. Return

Commonwealth Equity Services's ORMP Position: Q4 2022 in Review

Commonwealth Equity Services sold out of Oramed Pharmaceuticals (ORMP) in Q4 2022, closing a stake of 30,014 shares — an estimated $194K sold.

Commonwealth Equity Services first reported a position in ORMP in Q1 2021 and held it in 7 quarters. The position peaked at $595K in Q3 2021. 77 funds tracked by Wall St. Rank hold ORMP as of Q4 2022.

Commonwealth Equity Services reported no remaining Oramed Pharmaceuticals position as of Q4 2022 after selling out during the quarter.
Commonwealth Equity Services sold 30,014 Oramed Pharmaceuticals shares in Q4 2022, an estimated $194K.
Commonwealth Equity Services first reported a position in Oramed Pharmaceuticals in Q1 2021 and held it in 7 quarters.
Commonwealth Equity Services's Oramed Pharmaceuticals position peaked at $595K in Q3 2021.
77 funds tracked by Wall St. Rank held Oramed Pharmaceuticals as of Q4 2022.

Based on Commonwealth Equity Services's 13F filing for Q4 2022, filed 7 Feb 2023.